Drugdocs | Kengreal

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Kengreal

Chemical Name	cangrelor
Dosage Form	Injection (intravenous; 50 mg/ 10 mL)
Drug Class	Inhibitors
System	Cardiovascular
Company	Chiesi USA Inc
Approval Year	2015

Indication

Indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.

Last updated on 10/13/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Kengreal (cangrelor) Prescribing Information	2019	Chiesi USA, Inc., Cary, NC

Document Title	Year	Source
Meta-analysis of comparison of the newer p2y12 inhibitors (oral preparation or intravenous) to clopidogrel in patients with acute coronary syndrome.	2017	Journal of Cardiovascular Pharmacology

Document Title	Year	Source
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).	2015	European Heart Journal